Gundolf Schüttfort1, Timo Wolf2, Phillip de Leuw2, Gerrit Kann2, Maximilian Blume3, Hans-Reinhard Brodt2, Christoph Stephan2. 1. Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany. dcgundolf@yahoo.de. 2. Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany. 3. Department for Orofacial Surgery, Goethe-University Hospital, Frankfurt am Main, Germany.
Abstract
INTRODUCTION: Kaposi's sarcoma (KS) is a rare vascular tumor that may occur in a severe, rapidly progressive form, namely in HIV/AIDS patients. HIV-associated KS mainly affects the skin and mucous membranes. CASE PRESENTATION: We report about an HIV-positive patient who presented with an exophytic growing tumor in the region of the hard palate and severe problems regarding his dental status. Histological examination revealed evidence of AIDS-related KS. Antiretroviral therapy initiation with elvitegravir/cobicistat/emtricitabine(FTC)/tenofovirdisoproxilfumarat (E/c/F/T-fix dose combination) resulted in rapid complete remission of the KS within 2 months. CONCLUSION: In this case of a treatment-naive HIV-infected patient with coexisting KS, antiretroviral therapy with E/c/FTC/TDF was very well suited to achieve rapid complete remission of KS.
INTRODUCTION:Kaposi's sarcoma (KS) is a rare vascular tumor that may occur in a severe, rapidly progressive form, namely in HIV/AIDSpatients. HIV-associated KS mainly affects the skin and mucous membranes. CASE PRESENTATION: We report about an HIV-positive patient who presented with an exophytic growing tumor in the region of the hard palate and severe problems regarding his dental status. Histological examination revealed evidence of AIDS-related KS. Antiretroviral therapy initiation with elvitegravir/cobicistat/emtricitabine(FTC)/tenofovirdisoproxilfumarat (E/c/F/T-fix dose combination) resulted in rapid complete remission of the KS within 2 months. CONCLUSION: In this case of a treatment-naive HIV-infectedpatient with coexisting KS, antiretroviral therapy with E/c/FTC/TDF was very well suited to achieve rapid complete remission of KS.
Authors: J Pauk; M L Huang; S J Brodie; A Wald; D M Koelle; T Schacker; C Celum; S Selke; L Corey Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245
Authors: A Scott Laney; Michael J Cannon; Harold W Jaffe; Margaret K Offermann; Chin-Yih Ou; Kay W Radford; Mitesh M Patel; Thomas J Spira; Clifford J Gunthel; Philip E Pellett; Sheila C Dollard Journal: AIDS Date: 2007-07-31 Impact factor: 4.177
Authors: Mark Bower; Alessia Dalla Pria; Chris Coyle; Eileen Andrews; Victoria Tittle; Sharanjit Dhoot; Mark Nelson Journal: J Clin Oncol Date: 2013-12-30 Impact factor: 44.544
Authors: Mark Bower; Justin Weir; Nicholas Francis; Tom Newsom-Davis; Sam Powles; Tim Crook; Marta Boffito; Brian Gazzard; Mark Nelson Journal: AIDS Date: 2009-08-24 Impact factor: 4.177
Authors: S Franceschi; M Lise; G M Clifford; M Rickenbach; F Levi; M Maspoli; C Bouchardy; S Dehler; G Jundt; S Ess; A Bordoni; I Konzelmann; H Frick; L Dal Maso; L Elzi; H Furrer; A Calmy; M Cavassini; B Ledergerber; O Keiser Journal: Br J Cancer Date: 2010-06-29 Impact factor: 7.640